patients with non-surgical stage disease (n¼10); 2) imprinted cytological samples from positive mediastinoscopies during the intraoperative staging of patients with lung cancer (n¼11); 3) positive pleural fluid in patients with pulmonary nodule (n¼2). Then we performed FISH technique, evaluated the quality of the signal obtained, and compared the results with those obtained on paraffin sections. FISH technique on paraffin blocks was performed using 2XSSC/ proteinase K pretreatment as standardized by our lab. Cytology smears were destained and fixed in 10% methanol and incubated with FISH probe (ALK, ROS1 and MET). Result: All cytology cases had scorable signals and were easy to interpret. Also, as no pretreatment was required, assay time was shorter. Depending on cellularity, one same slide was useful for analysis of the three probes. When comparing with IHC and FISH studies, we obtained a 100% correlation with ALK (n¼23; positive¼2, negative¼21), ROS1 (n¼5, all negative) and MET (n¼5, all negative). Conclusion: This work allowed us to optimize the use of different cytology samples frequently available in advance stage NSCLC for FISH studies. The use of cytological material might improve turnaround time for results and can become a useful tool in pathology labs, in particular when paraffin included material is limited.
P2.01-76 The Impact of Concordance with a Lung Cancer Diagnosis Pathway Guideline on Treatment Access in Patients with Stage IV Lung Cancer A. Pattison, 1 L. Jeagal, 2 J. Yeung, 1 A. Pierre, 1 L. Donahoe, 1 M. Cypel, 1 M. De Perrot, 1 K. Yasufuku, 1 G. Darling, 1 T. Waddell, 1 S. Keshavjee, 1 K. Czarnecka-Kujawa 1 1 Division of Thoracic Surgery, Toronto General Hospital, University Health Network, University of Toronto, Toronto, ON/CA, 2 University of Toronto, Toronto, ON/CA Background: Lung cancer is the leading cause of cancer mortality with the majority of cases diagnosed at an advanced stage. Timely access to treatment is dependent on efficient and appropriate patient assessment and early referral for diagnostic workup. This study aims to assess the impact of referral concordance with a new Lung Cancer Diagnostic Pathway Guideline (LCDPG) on access to treatment in patients with stage IV lung cancer. Method: This is a retrospective cohort study of patients with clinical stage IV lung cancer referred to the Diagnostic Assessment Program (DAP) at a Canadian tertiary cancer centre between November 1, 2015 and May 31, 2017. Patient referrals were defined as concordant or discordant based on Cancer Care Ontario LCDPG. The primary outcome; time to treatment from initial healthcare presentation; was compared between the concordant and discordant referrals. Result: Two hundred patients were referred for clinical stage IV lung cancer during the study period. Of these referrals, 151 (75.5%) were assessed and referred in concordance with LCDP guidelines. Guideline concordant referrals were associated with reduced time to treatment from first healthcare presentation compared with guideline discordant referrals (55.3 vs 108.8 days, p<0.001). Time to diagnostic procedure (32.2 vs 86.7 days, p<0.001) and decision to treat (38.5 vs 93.8 days, p<0.001) was also reduced with guideline concordance. The most common reason for discordant assessment and referral was delayed or inadequate investigation of symptoms in a high risk patient (32.7% of discordant referrals). The mean time from referral to diagnostic procedure (19.4 [SD 16 .0] days), decision to treat (23.3 [SD 17.1] days), and treatment initiation (39.7 [SD 26 .3] days) did not significantly differ between concordant and discordant groups. Time from referral to decision to treat was within 28 days in 71.5% of patients. The mean number of hospital visits from referral to treatment was 4.9 (SD 3.5). Diagnosis was achieved with a single diagnostic test in the majority of patients (91%). The most common method of diagnosis was EBUS-TBNA (33.5%). The most common treatment modalities initiated were radiation (60.5%) followed by chemotherapy (43%) The current study aimed to assess correlation between KPS and ECOG PS in a large cohort from a lung cancer (LC) clinic database and to determine KPS categories which were most equivalent to ECOG PS scores. Method: All patients attending LC clinic at a tertiary care centre over a 5-year period were assessed with both KPS and ECOG PS scales at each visit. Correlation between KPS and ECOG PS was assessed using Spearman's correlation coefficient. Different KPS categories equivalent to ECOG PS were compared using hit rate and weighted kappa (k w ). Result: A total of 1501 patients were assessed over study period providing 5844 paired KPS and ECOG PS assessments. The cohort had a mean (standard deviation SD) age of 58.4 (10.8) years with majority being current/exsmokers (76.9%) and males (82.3%). NSCLC was commonest histological type (n¼1196, 79.7%) with majority having advanced (stages IIIB/IV) disease (83.4%). Mean baseline KPS and ECOG PS scores were 77.6 (SD¼14.4) and 1.5 (SD¼1) respectively. Overall correlation between KPS and ECOG PS was good [Spearman r ¼ (-)0.84, P<0.0001] but ranged from -0.727 to -0.972 between visits. KPS categories derived from our cohort (10- 
